Ingelvac PRRS ATPThis page contains information on Ingelvac PRRS ATP for veterinary use.
The information provided typically includes the following:
- Ingelvac PRRS ATP Indications
- Warnings and cautions for Ingelvac PRRS ATP
- Direction and dosage information for Ingelvac PRRS ATP
Ingelvac PRRS ATPThis treatment applies to the following species:
Porcine Reproductive and Respiratory Syndrome Vaccine
Reproductive and Respiratory Forms, Modified Live Virus
Read entire insert before use.
This product is manufactured by Boehringer Ingelheim Vetmedica, Inc. Call Customer Service toll free at 1-800-325-9167 with any questions.
For new or additional information on the latest in PRRS virus research, and to answer any questions on Ingelvac PRRS® ATP, contact Boehringer Ingelheim Professional Services toll free at 1-800-325-9167.
Ingelvac PRRS ATP Indications
Recommended for the vaccination of healthy, susceptible swine as an aid in the reduction of disease associated with Porcine Reproductive and Respiratory Syndrome virus, reproductive and respiratory forms.
Recommended for use in healthy, susceptible swine in PRRS virus positive herds only, per label directions.
Rehydrate the vaccine by adding the full contents of the accompanying liquid diluent to the vaccine vial. Shake well and use immediately. Rehydrate only with the diluent provided; do not mix with other materials.
Sows and Gilts: Using aseptic technique, inject a single 2 mL dose intramuscularly at 3 to 4 weeks prior to breeding for the reproductive form of PRRS. The duration of immunity is at least 4 months or throughout gestation.
Piglets: Using aseptic technique, administer a single 2 mL dose intramuscularly to swine 3 weeks of age or older for the respiratory form of PRRS. The duration of immunity is at least 4 months or throughout the finishing period.
Administer only to healthy pigs, gilts, or sows in PRRS virus positive herds, and only by intramuscular injection. Do not vaccinate breeding age boars or pregnant females. Administer the complete 2 mL dose to each animal vaccinated. Efficacy and safety of the vaccine at other than the dose or route prescribed on the label is unknown and, therefore, not recommended and not USDA approved. Anaphylactoid reactions may occur. Specific herds may be particularly sensitive. Antidote: Epinephrine.
Store out of direct sunlight in the outer carton, at a temperature between 35-45°F (2-7°C). Do not freeze. Use entire contents when first opened. Do not use bottles of damaged product. Do not store reconstituted vaccine.
Vaccinated pigs are not to be harvested for human consumption before 21 days after vaccination.
After use, burn containers and all unused contents by a procedure allowed by local, state, and Federal regulations.
Consult the outer carton for the last date this package of vaccine is acceptable for use.
If human exposure occurs, administer first aid and consult a physician immediately.
Many factors must be considered in determining a sound PRRS vaccination program for a particular farm. To be most effective, the vaccine must be administered properly to healthy animals maintained in a proper environment under good management. Stressed or immunosuppressed pigs should not be vaccinated, as the efficacy of the vaccine in these animals is unknown. The level of individual animal and herd immunity required will vary with management practices, the degree of exposure to PRRS virus, and the level of susceptibility of each animal. The benefits and risks from vaccination will vary in part with the levels of PRRS virus in the herd, and the need for the herd or individual animals to maintain a particular status for virus isolation, serological, or other diagnostic tests. Therefore, the vaccination program must be carefully planned and implemented in collaboration with the herd veterinarian following label and insert indications and precautions.
Previous Or Active Prrs Virus Or Other Infection
The effect of concurrent or previous infections at or around the time of vaccination on the efficacy of this vaccine in reducing or modifying PRRS virus disease in pigs is not known.
Shedding And Transmission Of Vaccine Virus By Vaccinates
Vaccine virus may be shed and transmitted to other populations of swine which are in contact, with vaccinated swine. The duration of potential vaccine virus transmission may vary.
Vaccine virus is found at varying times post-vaccination at locations (tonsil, nasal mucosa, urine, feces) from which the potential for shedding exists. The chances of vaccine virus shedding may be increased when animals are treated with glucocorticoids and possibly by disease or environmental conditions which stress pigs and elevate levels of endogenous glucocorticoids.
Nonvaccinated pigs in contact with Ingelvac PRRS® ATP vaccinated pigs may seroconvert to vaccine virus. Use of the vaccine on farms or transport of pigs from the farms where vaccine has been used to farms wanting to remain PRRS virus seronegative is contraindicated.
Vaccination during the latter part of gestation of pregnant sows or gilts which are PRRS virus naive and previously unvaccinated can result in piglets born vaccine viremic. The impact of vaccine viremia in the newborn pig is not known.
Vaccination of adult boars may result in the shedding of vaccine virus in the semen. Because the impact of shedding is not known, do not use in boars of breeding age.
Ingelvac PRRS® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH.
© 2013 Boehringer Ingelheim Vetmedica, Inc. All Rights Reserved.
Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO 64506
US Vet. Lic. No. 124
50 Doses/Rehydrate with 100 mL
This package contains one 50 dose vial of vaccine and one 100 mL vial of sterile diluent.
NAC No.: 1028067.3
3239 SATELLITE BLVD., DULUTH, GA, 30096
|Every effort has been made to ensure the accuracy of the Ingelvac PRRS ATP information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2019 Animalytix LLC. Updated: 2019-09-30